Pipeline-in-a-drug, page-8

First 8 Last

Share
Profile

Follow
NZ Trader

13,635 Posts.

7353

05/06/24

10:52

Post #: 74171028
Share

Originally posted by ma420: ↑

Not cross promoting but look at RAC which will soon be trialled in an ‘All-comers’ trial across any cancer indication. The reason is they are testing for cardio-protection which is protecting the heart muscles when used with standard of care anthracyclines like Doxorubicin (Dox) and Decitabine (Dec) among others.

Dox is predominantly used in solid tumours and Dec in blood cancers. So irrespective of which cancer Race’s Bisantrene is used in, any positive benefits seen on the patient’s heart will be taken as evidence of Bisantrene’s efficacy as the efficacy (and lack of heart safety) of Dox & Dec are known. So in that context Bisantrene is another case of a pipeline in a drug. Look at the Triangle report which was an independent third party report on the potential of something like Bisantrene which was blinded to the surveyed.

Again, I repeat this is not a cross promotion but just highlighting how wide the market can be and how big the TAM can be, and hence the valuation in any M&A.

AIMO. DYOR.

Disclosure: I hold Race oncology (RAC)

Expand

Wasn't RAC performance just text book 9c to $4 incredible ,,,, made gains on every announcement on the way up ....

PAA under new stewardship may well be able to emulate RAC .... lets hope ,,NZT

PAA Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
24 Upvote

0 Great analysis

Reply

Top Stories

Tuesday's HotCopper trends: Sayona intercepts, Bowen Coking crisis | July 15

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

WIN

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

AII

Inside the depths of Panasqueira: A legacy carved in rock

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

First 8 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.0¢		Change -0.010(5.88%)		Mkt cap ! $78.76M

Open	High	Low	Value	Volume
16.5¢	17.0¢	16.0¢	$57.71K	349.8K

Buyers (Bids)

No.	Vol.	Price($)
4	71829	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	2606	1

View Market Depth

No.	Vol.	Price($)
4	71829	0.160
6	158848	0.155
8	128707	0.150
2	303482	0.145
1	7135	0.140

Price($)	Vol.	No.
0.165	2606	1
0.170	227136	4
0.175	20000	2
0.180	522500	6
0.185	109375	3

Last trade - 15.31pm 15/07/2025 (20 minute delay)

NUZ (ASX) Chart

Pipeline-in-a-drug, page-8

Tuesday's HotCopper trends: Sayona intercepts, Bowen Coking crisis | July 15

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

Inside the depths of Panasqueira: A legacy carved in rock

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-8

Top Stories

Tuesday's HotCopper trends: Sayona intercepts, Bowen Coking crisis | July 15

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

Inside the depths of Panasqueira: A legacy carved in rock

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News